DAB has developed a unique bioreactor technology that increases the productivity of the fermentation process. At the same time, it reduces the operational costs with 50%. Using this technique, products made with fermentation become more affordable and competitive with fossil processes. Application of this technology on a large scale is expected to accelerate the transition to a bio-based economy. DAB licenses its technology to large industrial parties that integrate it into their existing production processes.
Kirsten Steinbusch, CEO of DAB: ‘We recently received an investment of € 2 million, making the move to the Biotech Campus Delft a logical next step. We want to further develop our technology and to accelerate our commercial growth. To scale up our technology, we work closely with the TU Delft and with an established partner on the Biotech Campus, the Bioprocess Pilot Facility (BPF). Thanks to the good facilities available at the Biotech Campus Delft, we now can explore new market applications and further optimize our techniques.’ ‘We are delighted to welcome DAB at the Biotech Campus,’ says Raimo van der Linden, Business Development Manager at Bioprocess Pilot Facility (BPF). ‘It offers great benefits for both DAB and BPF. The BPF has extensive expertise in scaling up production, even on an industrial scale. We are happy to support DAB with our knowledge, infrastructure, permits and the use of our test factory.’
Cindy Gerhardt, Business Development Director of the Biotech Campus Delft, is also pleased to welcome DAB at the campus. ‘DAB is the third innovative Biotech company that settles at the campus, and we are not even officially open! DAB is a wonderful example of the unique strength of Delft in biotechnology; an idea originating from research at the TU in Delft, was incubated as a start-up at YES!Delft, and now moves to our campus to get access to all the facilities needed for upscaling and commercial growth. Together, we can realize the transition to a sustainable bio-based economy!’